All Articles

OPAL Fuels is set to report Q2 earnings on Aug 10. Amid volatile RIN prices and new EPA rules, investors will scrutinize production growth and profitability.

iA Clarington's new fund isn't just another product. It's a strategic play blending quantitative precision with the accessible ETF structure. Here's why.

Waters Corp. has launched a mass spectrometer promising a new era of diagnostic sensitivity. But can its operational robustness overcome the real-world hurdles?

Pilot Games' new patent for e-pull-tabs isn't just a tech upgrade; it's a strategic move in a billion-dollar market where IP is the ultimate jackpot.

Prospect Enhanced Yield Fund boosts its dividend to an 11.5% annualized rate, sending a strong signal of confidence in the structured credit market.

A new CMS mandate puts hospitals at a financial crossroads. A new report shows how AI can turn this compliance burden into an $85M revenue opportunity.

Lincoln Memorial University is launching a 3-year teaching degree to combat Appalachia's dire teacher shortage. Is this radical experiment the future of higher ed?

Labcorp's new direct-to-consumer genetic panel promises early risk detection. But does it create a new set of challenges for patients and doctors?

Following a strategic merger and a $200M financing round, Yarrow Bioscience is advancing a novel drug for autoimmune thyroid disease. But can it disrupt a market dominated by incumbents?

A new standards body has emerged to regulate how AI interacts with human cognition. But with proprietary science and a low-profile founder, the bid to build public trust faces its first major test.

New research reveals a costly side effect of hybrid work: a 'coordination tax' that costs firms millions and frustrates employees. Are you paying it?

High Liner Foods is betting on quick, global seafood meals to disrupt the frozen food aisle. A deep dive into the strategy, market, and systems behind it.

Unisport taps marketing veteran Denise Karkos to lead its global charge. We explore how this is less about a new hire and more about a new digital playbook.

As PPHC preps for its Q2 results, the strategic communications giant faces a key test. Can its aggressive M&A and strong growth narrative overcome market jitters?

A breakthrough trial for a rare genetic disorder unlocks $50M in funding. We explore the novel RNA science, the savvy investment, and why it's all happening in Australia.

With the hire of Abecma veteran Dr. Steven Bernstein, Liberate Bio signals its readiness to take its 'off-the-shelf' CAR-M therapy into the clinic.

As millions face retirement without pensions, innovative annuities are filling the gap. Global Atlantic's award-winning RILA shows how investors are finding a new middle ground.

As GCT prepares its Q2 update, investors are looking past the numbers to its progress in the AI-Edge data pipeline, satellite comms, and 5G partnerships.

Teladoc Health Canada's new accreditation isn't just a plaque on the wall. It’s a strategic move setting a new benchmark for quality in the digital health race.

CEO Johan Wattenström paints a picture of unprecedented strength amid a crypto winter, but a closer look reveals a strategy forged in regulatory fire.